New insights on translational development of mesenchymal stromal cells for suppressor therapy

Journal of Cellular Physiology

Volumn 227, Issue 11, 2012, Pages 3535-3538

  François, Moïra ^a   Galipeau, Jacques ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; AUTOIMMUNE DISEASE; CELL TRANSPLANTATION; CELL VIABILITY; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TISSUE REGENERATION; TRANSLATIONAL RESEARCH;

ANIMALS; AUTOIMMUNE DISEASES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STROMAL CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGENERATION; TISSUE THERAPY; TRANSLATIONAL MEDICAL RESEARCH;

ANIMALIA;

EID: 84864110915     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24081     Document Type: Short Survey

References (42)

1. Aggarwal S, Pittenger MF. 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815- 1822.
2. Caplan AI, Correa D. 2011. The MSC: An injury drugstore. Cell Stem Cell 9: 11- 15.
3. Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, Bertoni A, Frassoni F, Bartolome ST, Sambuceti G, Traggiai E, Uccelli A. 2011. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 108: 17384- 17389.
4. Choumerianou DM, Martimianaki G, Stiakaki E, Kalmanti L, Kalmanti M, Dimitriou H. 2010. Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults. Cytotherapy 12: 881- 887.
5. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR. 2011. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60: 788- 798.
6. Di NM, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838- 3843.
7. English K, Mahon BP. 2011. Allogeneic mesenchymal stem cells: Agents of immune modulation. J Cell Biochem 112: 1963- 1968.
8. English K, Barry FP, Mahon BP. 2008. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 115: 50- 58.
9. Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC, Ma Y. 2007. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 11: 814- 817.
10. Francois M, Galipeau J. 2011. Chapter 6. Mesenchymal stromal cells: An emerging cell-based pharmaceutical. Experimental and Applied Immunotherapy. Bethesda: Humana Press. pp 127- 148.
11. Francois M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. 2012a. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 14: 147- 152.
12. Francois M, Romieu-Mourez R, Li M, Galipeau J. 2012b. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20: 187- 195.
13. Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De La Quintana P, Garcia-Arranz M, Pascual M. 2009. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 52: 79- 86.
14. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. 2002. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 8932- 8937.
15. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. 2010. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67: 1187- 1194.
16. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. 2009. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15: 804- 811.
17. Kim J, Hematti P. 2009. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol 37: 1445- 1453.
18. Krampera M. 2011. Mesenchymal stromal cell 'licensing': A multistep process. Leukemia 25: 1408- 1414.
19. Kuzmina LA, Petinati NA, Parovichnikova EN, Lubimova LS, Gribanova EO, Gaponova TV, Shipounova IN, Zhironkina OA, Bigildeev AE, Svinareva DA, Drize NJ, Savchenko VG. 2012. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-A phase II study. Stem Cells Int 2012: 968213.
20. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Jr., Moseley AB, Bacigalupo A. 2005. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11: 389- 398.
21. Le BK, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lonnies H, Nava S, Ringden O. 2007. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733- 1738.
22. Le BK, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O. 2008. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371: 1579- 1586.
23. Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L. 2010. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann Rheum Dis 69: 1423- 1429.
24. Maijenburg MW, Kleijer M, Vermeul K, Mul EP, van Alphen FP, van der Schoot CE, Voermans C. 2012. The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging. Haematologica 97: 179- 183.
25. Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, Herrmann RP, Kebriaei P. 2010. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 16: S169- S170.
26. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. 2004a. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619- 4621.
27. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. 2004b. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619- 4621.
28. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. 2009. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42- 49.
29. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J. 2011. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17: 534- 541.
30. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, Forner K, Boivin MN, Doody K, Tremblay M, Annabi B, Galipeau J. 2008. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112: 4991- 4998.
31. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. 2008. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 251: 131- 136.
32. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. 2008. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141- 150.
33. Ren G, Su J, Zhang L, Zhao X, Ling W, L'huillie A, Zhang J, Lu Y, Roberts AI, Ji W, Zhang H, Rabson AB, Shi Y. 2009. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27: 1954- 1962.
34. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le BK. 2006. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81: 1390- 1397.
35. Ryan JM, Barry F, Murphy JM, Mahon BP. 2007. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149: 353- 363.
36. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. 2007. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109: 228- 234.
37. Siddappa R, Licht R, van BC, de BJ. 2007. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res 25: 1029- 1041.
38. Stagg J, Galipeau J. 2007. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol 180: 45- 66.
39. Uccelli A, Moretta L, Pistoia V. 2008. Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726- 736.
40. von BM, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M. 2009. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43: 245- 251.
41. Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC. 2004. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13: 263- 271.
42. Zhukareva V, Obrocka M, Houle JD, Fischer I, Neuhuber B. 2010. Secretion profile of human bone marrow stromal cells: Donor variability and response to inflammatory stimuli. Cytokine 50: 317- 321.